The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency
The Effects of Iron Treatment on Malaria, Typhoid and Measles Vaccine Response in Kenyan Infants With Iron Deficiency: A Randomized Controlled Trial
Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination.
In this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21/Matrix-M, Typhim VI and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Nicole Stoffel, PhD
- Phone Number: +41 044 632 83 93
- Email: nicole.stoffel@hest.ethz.ch
Study Contact Backup
- Name: Lara Del Curto, MSc
- Phone Number: +41 0774212070
- Email: lara.delcurto@pharma.ethz.ch
Study Locations
-
-
Kwale County
-
Msambweni, Kwale County, Kenya, 80404
- Recruiting
- Msambweni District Hospital
-
Contact:
- Edith Mwasi, MD
- Email: edithmwasi@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject's caregiver is willing and able to give informed consent
- Male or Female, 6 months (+/- 2 weeks) of age
- Mother ≥15 years of age
- Iron deficient (erythrocyte zinc protoporphyrin (ZnPP) >61 μmol/mol heme) or anemic (hemoglobin (Hb) <105 g/L)
Exclusion Criteria:
- Severely anemic (Hb <70 g/L)
- Hemoglobinopathies HbCC, HbSC, or HbSS
- Malaria, Measles or Typhoid vaccination prior to enrollment
- Medical condition that precludes study involvement
- Iron supplementation 2 weeks before enrollment
- Acute or chronic infection (e.g. HIV)
- Wasted (length for height z score of ≥-2) or underweight (weight for age z score ≥-2).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Iron treatment group
daily multivitamin + daily iron syrup from age 6 to 10 months |
Iron syrup administered daily from 6 to 10 months of age. Multivitamin syrup administered daily from 6 to 10 months of age. R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age. Measles-Rubella vaccine administered at 9 months of age. |
|
Other: Control group
daily multivitamin syrup from age 6 to 10 months |
Multivitamin syrup administered daily from 6 to 10 months of age. R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age. Measles-Rubella vaccine administered at 9 months of age. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NANP-specific IgG
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG antibodies targeting the NANP repeat region of the circumsporozoite protein (CSP) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Anti-measles IgG
Time Frame: At 10 months of age (1 month after MR vaccine administration)
|
IgG antibodies targeting measles antigen |
At 10 months of age (1 month after MR vaccine administration)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anti-typhoid IgG
Time Frame: At 10 months of age (1 month after Typhim VI administration)
|
IgG antibodies targeting typhoid antigen |
At 10 months of age (1 month after Typhim VI administration)
|
|
C-terminal-specific IgG
Time Frame: At 10 months of age (1 month after 3rd R21/Matrix-M dose)
|
IgG antibodies targeting the C-terminal region of CSP |
At 10 months of age (1 month after 3rd R21/Matrix-M dose)
|
|
C-terminal-specific IgG
Time Frame: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
IgG antibodies targeting the C-terminal region of CSP |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
C-terminal-specific IgG
Time Frame: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
IgG antibodies targeting the C-terminal region of CSP |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
|
NANP-specific IgG
Time Frame: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
IgG antibodies targeting the NANP repeat region of CSP |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
NANP-specific IgG
Time Frame: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
IgG antibodies targeting the NANP repeat region of CSP |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
|
Full-length CSP-specific IgG
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG antibodies targeting the full-length CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgM
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgM antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgA
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgA antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG4
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG4 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG3
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG3 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG2
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG2 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG1
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG1 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
IgG avidity to measles antigen
Time Frame: At 10 months of age (1 month after MR vaccine administration)
|
Avidity index for IgG binding to measles antigen |
At 10 months of age (1 month after MR vaccine administration)
|
|
IgG avidity to typhoid antigen
Time Frame: At 10 months of age (1 month after Typhim VI administration)
|
Avidity index for IgG binding to typhoid antigen |
At 10 months of age (1 month after Typhim VI administration)
|
|
IgG avidity to NANP-specific CSP
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Avidity index for IgG binding to NANP CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
IgG avidity to C-terminal CSP
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Avidity index for IgG binding to C-terminal CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Full-length CSP-specific IgG seropositivity
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
C-terminal-specific IgG seropositivity
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
C-terminal-specific IgG seropositivity
Time Frame: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
C-terminal-specific IgG seropositivity
Time Frame: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
|
NANP-specific IgG seropositivity
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG seropositivity
Time Frame: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
NANP-specific IgG seropositivity
Time Frame: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Inhibition of Plasmodium falciparum sporozoite-invasion of HC-04 hepatic cells
Time Frame: At 10 months of age (1 months after the 3rd R21/Matrix-M dose)
|
Exploratory in vitro assay on IgG functionality in lowest and highest responders |
At 10 months of age (1 months after the 3rd R21/Matrix-M dose)
|
|
Opsonic phagocytosis of CSP-coated beads by THP-1 cells
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Exploratory in vitro assay of IgG opsonization functionality in lowest and highest responders |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells
Time Frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Exploratory in vitro assay performed in lowest and highest responders |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Antibody levels against a panel of antigens associated with malaria exposure in the previous year
Time Frame: At 7 months of age (baseline)
|
Exploratory in all participants |
At 7 months of age (baseline)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Nicole Stoffel, PhD, ETH Zurich
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vector Borne Diseases
- Mosquito-Borne Diseases
- Metabolic Diseases
- Infections
- RNA Virus Infections
- Virus Diseases
- Protozoan Infections
- Parasitic Diseases
- Iron Metabolism Disorders
- Paramyxoviridae Infections
- Mononegavirales Infections
- Morbillivirus Infections
- Nutritional and Metabolic Diseases
- Iron Deficiencies
- Malaria
- Measles
- Biological Products
- Complex Mixtures
- Vaccines
- Protozoan Vaccines
- Malaria Vaccines
Other Study ID Numbers
Other Study ID Numbers
- MEMA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.